Omary MB, Lugea A, Lowe AW et al
R.RosenstockJ.WyshamC.UngerJ.BellidoD.Gonzlez-GlvezG.et al (2016)
Similarly, an analysis utilizing the UK Clinical Practice Research Datalink (CPRD) revealed that GLP-1 RAs were linked to an increased incidence of intestinal obstruction requiring hospitalization, compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors (1.9 vs
Far too many hurdles continue to prevent people living with obesity from accessing obesity treatments that could lead to significant weight loss, said Mike Mason, executive vice president and president, Lilly Diabetes and Obesity
Some are raising the BMI threshold and requiring diabetes as a prerequisite
Therefore, the benefits of GLP-1 and GLP-1-based therapies for the cardiovascular system have attracted increased attention from clinicians